You are here

AusPAR: Blinatumomab

Related information


How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Australian Public Assessment Report

23 October 2019
AusPAR Details
AusPAR
Active Ingredient
Blinatumomab
Product Name
Blincyto
Sponsor
Amgen Australia Pty Ltd
Submission Number
PM-2017-01431-1-4
Submission Type
Extension of indications
Decision
Approved
AusPAR Date
30 September 2019
Publication Date

23 October 2019